About intellia therapeutics inc. - NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
NTLA At a Glance
Intellia Therapeutics, Inc.
40 Erie Street
Cambridge, Massachusetts 02139
| Phone | 1-857-285-6200 | Revenue | 67.67M | |
| Industry | Biotechnology | Net Income | -412,694,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 16.922% | |
| Fiscal Year-end | 12 / 2026 | Employees | 377 | |
| View SEC Filings |
NTLA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14.398 |
| Price to Book Ratio | 1.557 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.453 |
| Enterprise Value to Sales | 9.129 |
| Total Debt to Enterprise Value | 0.151 |
NTLA Efficiency
| Revenue/Employee | 179,498.674 |
| Income Per Employee | -1,094,679.045 |
| Receivables Turnover | 7.147 |
| Total Asset Turnover | 0.067 |
NTLA Liquidity
| Current Ratio | 5.08 |
| Quick Ratio | 5.08 |
| Cash Ratio | 4.331 |
NTLA Profitability
| Gross Margin | 76.47 |
| Operating Margin | -651.668 |
| Pretax Margin | -609.854 |
| Net Margin | -609.854 |
| Return on Assets | -40.597 |
| Return on Equity | -53.48 |
| Return on Total Capital | -53.966 |
| Return on Invested Capital | -45.851 |
NTLA Capital Structure
| Total Debt to Total Equity | 13.901 |
| Total Debt to Total Capital | 12.204 |
| Total Debt to Total Assets | 11.083 |
| Long-Term Debt to Equity | 9.957 |
| Long-Term Debt to Total Capital | 8.742 |